Morningstar

Verastem Inc VSTM

Stock XNAS Rating as of Oct 27, 2026

News

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

Business Wire Oct 22, 2026, 11:30:00 AM
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Business Wire Oct 14, 2026, 10:04:00 AM
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Business Wire Oct 14, 2026, 10:01:00 AM
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

Business Wire Oct 14, 2026, 10:00:00 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Oct 5, 2026, 8:02:00 PM
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

Business Wire Oct 2, 2026, 11:30:00 AM
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire Sep 28, 2026, 8:10:00 PM
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

PR Newswire Sep 28, 2026, 12:00:00 PM
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

Business Wire Sep 24, 2026, 12:30:00 PM
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

Business Wire Sep 8, 2026, 11:30:00 AM
Verastem Oncology to Participate in Upcoming September Investor Conferences

Business Wire Sep 2, 2026, 11:30:00 AM
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Business Wire Aug 6, 2026, 8:01:00 PM
Verastem Doses First Patient in Pancreatic Cancer Trial

Global News Select Jun 16, 2026, 8:49:00 PM
Verastem Oncology Gets FDA Fast Track Designation for Lung Cancer Drug

Global News Select Jun 3, 2026, 9:03:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.